Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Apple Turns 50: From Garage Startup to AI Crossroads 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
 shares announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Nov. 29, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in New York on behalf of certain purchasers of shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) over alleged Securities Laws Violations by Alexion Pharmaceuticals, Inc.
Investors who purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have certain options and for certain investors there are short and strict deadlines running. Deadline: January 17, 2017. NASDAQ: ALXN investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants issued materially false and misleading statements to investors and/or failed to disclose that Alexion Pharmaceuticals, Inc employed improper sales practices with respect to Soliris, that consequently, Alexion’s revenues from Soliris sales were unlikely to be sustainable, and that as a result, Alexion’s public statements were materially false and misleading at all relevant times.
On November 9, 2016, Alexion Pharmaceuticals, Inc announced that the Audit and Finance Committee of the Board of Directors is conducting an investigation into allegations that recently have been made by a former employee with respect to the Company’s sales practices of Soliris. Alexion Pharmaceuticals, Inc said that the Audit and Finance Committee is investigating whether Company personnel have engaged in sales practices that were inconsistent with Company policies and procedures and the related disclosure and other considerations raised by such practices and that the Audit and Finance Committee has retained outside counsel to assist it in the investigation.
Those who purchased Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
